Kyverna Therapeutics, Inc.

KYTX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$127-$60-$29-$26
Dep. & Amort.$2$2$1$1
Deferred Tax$0$0$0$0
Stock-Based Comp.$8$2$1$7
Change in WC$8$3-$10-$4
Other Non-Cash-$5$1$1$1
Operating Cash Flow-$114-$52-$36-$22
Investing Activities
PP&E Inv.-$2-$1-$1-$1
Net Acquisitions$0$0$0$0
Inv. Purchases-$490-$55-$56$0
Inv. Sales/Matur.$324$47$43$0
Other Inv. Act.$8$0$0$0
Investing Cash Flow-$161-$9-$14-$1
Financing Activities
Debt Repay.-$1-$1-$0-$0
Stock Issued$341$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$3$59$12$73
Financing Cash Flow$337$58$12$73
Forex Effect$0$0$0$0
Net Chg. in Cash$62-$3-$38$49
Supplemental Information
Beg. Cash$35$38$77$28
End Cash$97$35$38$77
Free Cash Flow-$116-$53-$37-$23
Kyverna Therapeutics, Inc. (KYTX) Financial Statements & Key Stats | AlphaPilot